
Annual report 2023
added 12-13-2025
MorphoSys AG Revenue 2011-2025 | MOR
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue MorphoSys AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 238 M | 278 M | 180 M | 328 M | 71.8 M | 76.4 M | 66.8 M | 49.7 M | 106 M | 64 M | 78 M | 51.9 M | 101 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 328 M | 49.7 M | 130 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
18.1 M | $ 4.76 | -0.69 % | $ 790 M | ||
|
Aclaris Therapeutics
ACRS
|
18.7 M | $ 3.03 | -0.33 % | $ 234 M | ||
|
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 0.22 | 23.77 % | $ 479 M | ||
|
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
912 K | $ 1.17 | - | $ 6.38 M | ||
|
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | ||
|
Celldex Therapeutics
CLDX
|
7.02 M | $ 26.37 | -1.71 % | $ 1.7 M | ||
|
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | ||
|
Ascendis Pharma A/S
ASND
|
364 M | $ 208.21 | -2.16 % | $ 5 B | ||
|
Aptevo Therapeutics
APVO
|
3.11 M | $ 0.59 | -36.45 % | $ 163 K | ||
|
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.16 | 2.1 % | $ 7.6 B | ||
|
Athersys
ATHX
|
5.51 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | ||
|
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
482 M | $ 94.44 | -0.62 % | $ 27.2 B | ||
|
Dynavax Technologies Corporation
DVAX
|
277 M | $ 15.38 | - | $ 2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
732 M | $ 26.88 | 0.26 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B | ||
|
Anika Therapeutics
ANIK
|
167 M | $ 9.54 | 0.65 % | $ 140 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | ||
|
Eton Pharmaceuticals
ETON
|
31.6 M | $ 16.96 | -0.16 % | $ 435 M | ||
|
Evogene Ltd.
EVGN
|
8.51 M | $ 1.01 | -3.81 % | $ 27.9 M | ||
|
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | ||
|
Exelixis
EXEL
|
2.17 B | $ 46.29 | -0.47 % | $ 13.4 B | ||
|
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
2.08 B | $ 585.38 | -0.98 % | $ 44.3 B | ||
|
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | ||
|
Foghorn Therapeutics
FHTX
|
22.6 M | $ 5.37 | -0.56 % | $ 295 M | ||
|
Aytu BioScience
AYTU
|
66.4 M | $ 2.47 | -2.57 % | $ 15.5 M | ||
|
AstraZeneca PLC
AZN
|
54.1 B | $ 92.54 | 0.1 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
113 M | $ 12.42 | 0.36 % | $ 818 M |